Nanobiotix S.A. — Form 6-K Summary
Reporting date: September 12, 2022. The filing is a Form 6-K submitted by Nanobiotix S.A., a French foreign private issuer, under Commission File No. 001-39777. The company files annual reports on Form 20-F.
Business Context and Reporting Period
The filing cover page identifies the company’s principal executive office at 60 Rue de Wattignies, 75012 Paris, France. It incorporates or furnishes Exhibit 99.1, described as a press release dated September 12, 2022; the press release text is not included in the provided filing content.
Financial Metrics
The provided text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating expenses, or other financial metrics.
Material Changes Versus Prior Period
The provided filing text does not describe material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, outlook, risk factors, contingencies, or unusual items. Any such information may be contained in Exhibit 99.1, which is referenced but not supplied.
Investor Verification Items
- Obtain and review Exhibit 99.1, the September 12, 2022 press release.
- Verify whether the press release contains financial results, clinical or business updates, guidance, financing information, or material risk disclosures.
- Confirm the filing’s associated exhibit and any subsequent SEC filings for additional context.
Filing Signatory
The filing was signed on September 12, 2022, by Bart Van Rhijn, Chief Financial Officer, on behalf of Nanobiotix S.A.